Li 2017.
| Study characteristics | ||
| Methods | Aim: to investigate the effect of escitalopram oxalate in the early treatment of post‐stroke depression, cognition and neurological function | |
| Participants | The diagnosis of ischaemic stroke was based on the Chinese guidelines for the diagnosis and treatment of acute ischaemic stroke (2010), and the diagnosis of haemorrhagic stroke was based on the Chinese diagnostic criteria for adult spontaneous cerebral haemorrhage (2010). Patient met the Chinese diagnostic criteria for mental disorders and depression, with HAMD ≥ 17 points. MMSE was used to screen the patients with post‐stroke cognitive impairment The patients with unstable vital signs, severe cognitive impairment, severe depression, severe aphasia and unconsciousness were excluded |
|
| Interventions | Both groups received routine medicine and rehabilitation exercise. The treatment group was additionally treated with escitalopram oxalate tablets (Lexpro, produced by Lingbei pharmaceutical factory of Denmark, Xi'an Janssen Pharmaceutical sub package), 10 mg orally after breakfast every day for 24 weeks; the control group was additionally treated with placebo, 1 tablet each time, orally after breakfast for 24 weeks | |
| Outcomes | HAMD, MMSE, NIHSS and FIM were used to evaluate depression, cognitive function, neurological deficit and the patients' ability to live independently respectively, by 2 psychiatrists and 2 neurologists who were uninformed of the treatment. Above scales were respectively before treatment, 4 weeks and 24 weeks after treatment | |
| Funding source | Unclear | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | No information |
| Allocation concealment (selection bias) | Unclear risk | No information |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | No information |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | Outcome assessed by 2 neurologist and 2 pyschiatrists unaware of treatment allocation |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | No information |
| Selective reporting (reporting bias) | Unclear risk | No information |
| Other bias | Unclear risk | No information |